EC approves Merck’s KEYTRUDA® (pembrolizumab) in combination with chemo for NSCLC
Merck announced the EC has approved KEYTRUDA, the company’s anti-PD-1 therapy, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for first-line treatment of adults with metastatic squamous non-small cell lung cancer. March 14, 2019